TitleAberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.
Publication TypeJournal Article
Year of Publication2013
AuthorsDe, Subhajyoti, Shaknovich Rita, Riester Markus, Elemento Olivier, Geng Huimin, Kormaksson Matthias, Jiang Yanwen, Woolcock Bruce, Johnson Nathalie, Polo Jose M., Cerchietti Leandro, Gascoyne Randy D., Melnick Ari, and Michor Franziska
JournalPLoS Genet
Volume9
Issue1
Paginatione1003137
Date Published2013
ISSN1553-7404
KeywordsB-Lymphocytes, Binding Sites, CCCTC-Binding Factor, Cell Line, Tumor, DNA Methylation, Epigenesis, Genetic, Gene Silencing, Genome, Human, Humans, Insulator Elements, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Promoter Regions, Genetic, Repressor Proteins
Abstract

<p>Despite mounting evidence that epigenetic abnormalities play a key role in cancer biology, their contributions to the malignant phenotype remain poorly understood. Here we studied genome-wide DNA methylation in normal B-cell populations and subtypes of B-cell non-Hodgkin lymphoma: follicular lymphoma and diffuse large B-cell lymphomas. These lymphomas display striking and progressive intra-tumor heterogeneity and also inter-patient heterogeneity in their cytosine methylation patterns. Epigenetic heterogeneity is initiated in normal germinal center B-cells, increases markedly with disease aggressiveness, and is associated with unfavorable clinical outcome. Moreover, patterns of abnormal methylation vary depending upon chromosomal regions, gene density and the status of neighboring genes. DNA methylation abnormalities arise via two distinct processes: i) lymphomagenic transcriptional regulators perturb promoter DNA methylation in a target gene-specific manner, and ii) aberrant epigenetic states tend to spread to neighboring promoters in the absence of CTCF insulator binding sites.</p>

DOI10.1371/journal.pgen.1003137
Alternate JournalPLoS Genet
PubMed ID23326238
PubMed Central IDPMC3542081
Grant ListR01 CA104348 / CA / NCI NIH HHS / United States
R01 GM096190 / GM / NIGMS NIH HHS / United States
U54 CA143798 / CA / NCI NIH HHS / United States